Sorafenib Articles
Stock Commentary - Europe - week to Oct 29, 2007
5 November 2007
CHMP backs Bayer Schering's Nexavar
1 October 2007
NCCN updates hepatobiliary cancer guidelines, adding Nexavar
17 September 2007
FDA accepts Nexavar HCC sNDA for review
3 September 2007
Nexavar to be given to all patients in Asia-Pacific trial after it boosts survival in HCC
3 September 2007
Bayer/Onyx submit US sNDA for Nexavar in HCC
2 July 2007
Bayer submits EMEA MAA for Nexavar in HCC
25 June 2007
Nexavar extends survival in liver cancer
11 June 2007
BIO survey rebuts Part D price negotiation plan
5 March 2007
Bayer buys Pharmonyx' distribution network
26 February 2007
UPDATE: Bayer/Onyx' Nexavar achieves excellent safety and efficacy results in Ph III HCC trial
19 February 2007
Nexavar sees very strong Ph III data in HCC
19 February 2007
Good Ph III data for Bayer/Onyx Nexavar
15 January 2007
Nexavar fails in Ph III melanoma study
11 December 2006
Schering AG buy boosts Bayer but charges take toll on profit; 3rd-qtr beats forecasts
4 December 2006
25 new drugs get AIFA coverage in Italy
6 November 2006
Industry bodies oppose annual revision of Japan
7 August 2006
EC approves Bayer's Nexavar for RCC
31 July 2006
Enrollment complete in two Ph III Nexavar trials
15 May 2006
Bayer AG sees record-breaking 1st qtr with EBIT up 8.2% to $1.56 billion on strong health care sales
8 May 2006
CHMP thumbs-up for Bayer's Nexavar
8 May 2006
Bayer Yakuhin sees 2005 sales rise 4%
1 May 2006
Onyx/Bayer's Nexavar gains EC Orphan Status
24 April 2006
Bayer/Onyx' Nexavar cleared by Swissmedic
3 April 2006
Bayer/Onyx launch Ph III Nexavar trial
27 February 2006
Astellas sees solid fiscal 1st-qtr 2006
20 February 2006
Stock Commentary - Europe - week to Jan 9
9 January 2006
Update: Bayer gets first, US, approval for Nexavar
9 January 2006
Bayer/Onyx' Sorafenib granted priority review by US FDA
19 September 2005
Stock Commentary - Europe
18 July 2005
Bayer/Onyx complete NDA for sorafenib
18 July 2005
Stock Commentary - Europe
30 May 2005
Stock Commentary - Europe
23 May 2005
Bayer/Onyx initiate PH III sorafenib trial
23 May 2005
UPDATE: Bayer sees 1st-qtr profits leap 50%
9 May 2005
Bayer 1st-qtr profits up 50%
9 May 2005
Bayer/Onyx unblind Ph III trial of RCC drug
25 April 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
